Does TRT cause heart attacks?

The 2023 TRAVERSE trial (5,200+ men, ~3 years mean follow-up) found no increased risk of cardiovascular death, MI, or stroke in TRT vs placebo. Atrial fibrillation and pulmonary embolism rates were slightly higher — manageable with monitoring.

What is the most common side effect of long-term TRT?

Erythrocytosis (raised haematocrit). Managed with dose reduction, switching delivery form, periodic phlebotomy, and routine 6-12 month monitoring. It's the side effect that needs the most attention but is fully manageable.

Is TRT safe for life?

In properly diagnosed hypogonadal men with adequate monitoring (full labs every 6-12 months), yes. Long-term safety is a function of monitoring, not the drug itself. Men without regular labs are taking on most of the risk.

Should I stop TRT to be safer?

If you're properly diagnosed and properly monitored, no. The cardiovascular and prostate risks that worried clinicians a decade ago have not held up in randomised data. Stopping carries its own risks (HPG axis recovery period, symptom return).

Is TRT Safe Long-Term?

Yes — in properly diagnosed hypogonadal men with adequate monitoring, long-term TRT is safe. The 2023 TRAVERSE trial (5,200 men, 5 years) found no increased cardiovascular risk vs placebo. Prostate cancer risk is not elevated. Erythrocytosis is the most common manageable side effect.

Cardiovascular risk — what TRAVERSE settled

The 2023 TRAVERSE trial (Lincoff et al., NEJM) randomised 5,246 hypogonadal men aged 45-80 with cardiovascular risk factors to TRT or placebo for a mean 33 months (max ~5 years).

Primary outcome (cardiovascular death, MI, stroke): no significant difference. TRT was non-inferior to placebo for major adverse cardiovascular events.

Atrial fibrillation, acute kidney injury, and pulmonary embolism rates were slightly higher in the TRT group — small absolute increases but worth monitoring.

This trial resolved a decade of conflicting observational data. Earlier signals of cardiovascular harm (Vigen 2013, Finkle 2014) have not held up in randomised data.

Prostate — not the risk it was thought to be

The 'saturation hypothesis' (Morgentaler) and subsequent meta-analyses have failed to find increased prostate cancer incidence in men on TRT vs untreated hypogonadal men.

PSA monitoring is standard during TRT (baseline, 3 months, 6 months, then annually) — primarily to detect pre-existing undetected disease earlier, not because TRT causes new cancers.

Untreated active prostate cancer remains a contraindication to TRT. Men with treated and stable disease can often be considered case-by-case with urology input.

Erythrocytosis — the side effect that matters most

TRT stimulates erythropoiesis, raising haematocrit. Significant rises (>54%) increase blood viscosity and venous thromboembolism risk.

Manageable with: dose reduction, switching from depot to gel/cream (smaller swings), periodic phlebotomy (blood donation), and regular monitoring at 3 months, 6 months, then annually.

Hydration and avoiding sleep apnea (which independently raises haematocrit) help.

Fertility, gynecomastia, sleep apnea

Fertility: TRT suppresses spermatogenesis. Reversible in most men after stopping, sometimes not. hCG or enclomiphene during TRT preserves it.

Gynecomastia: from estradiol shifts when aromatisation outpaces target range. Managed by dose adjustment or, rarely, an aromatase inhibitor.

Untreated sleep apnea can worsen on TRT — screen with home oxygen monitoring or sleep study if symptoms suggest it.

The monitoring schedule that makes TRT safe long-term

Week 6-8: total T, free T, sensitive estradiol, haematocrit.

Month 3: full repeat plus lipid panel, PSA (if >40).

Month 6: confirm steady state, full panel including PSA.

Annually after year one: total and free T, SHBG, estradiol, haematocrit, PSA, lipid panel, comprehensive metabolic panel, hsCRP.

Long-term safety is a function of monitoring, not the drug. Men on TRT without regular labs are taking on most of the risk this article describes; men with monitoring are not.

FAQs

Does TRT cause heart attacks?: The 2023 TRAVERSE trial (5,200+ men, ~3 years mean follow-up) found no increased risk of cardiovascular death, MI, or stroke in TRT vs placebo. Atrial fibrillation and pulmonary embolism rates were slightly higher — manageable with monitoring.
Does TRT cause prostate cancer?: No — multiple meta-analyses have failed to find increased prostate cancer incidence in TRT vs untreated hypogonadal men. PSA monitoring is standard practice during TRT to detect pre-existing disease, not because TRT causes new cancers.
What is the most common side effect of long-term TRT?: Erythrocytosis (raised haematocrit). Managed with dose reduction, switching delivery form, periodic phlebotomy, and routine 6-12 month monitoring. It's the side effect that needs the most attention but is fully manageable.
Is TRT safe for life?: In properly diagnosed hypogonadal men with adequate monitoring (full labs every 6-12 months), yes. Long-term safety is a function of monitoring, not the drug itself. Men without regular labs are taking on most of the risk.
Should I stop TRT to be safer?: If you're properly diagnosed and properly monitored, no. The cardiovascular and prostate risks that worried clinicians a decade ago have not held up in randomised data. Stopping carries its own risks (HPG axis recovery period, symptom return).

Related tools & guides

Free Testosterone Calculator (Vermeulen) →
Track free testosterone alongside total at every monitoring interval.
How Long Does TRT Take to Work →
The monitoring milestones that catch side effects early.
Enclomiphene vs TRT →
If long-term TRT concerns you, enclomiphene may be the better first move.

Get TRT designed around the monitoring schedule that makes it safe — no skipped labs, no subscription.

Message on WhatsApp